Paris, France, Cambridge, USA, June 24, 2026 – TISSIUM, a medical technology company pioneering biomorphic programmable polymers for tissue reconstruction, today announced a €60 million financing package combining a completed €30 million Series D2 financing with a €30 million financing facility from the European Investment Bank (EIB).